PMID- 37720223
OWN - NLM
STAT- MEDLINE
DCOM- 20230928
LR  - 20230928
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed 
      cell death protein-1 inhibitors for advanced cholangiocarcinoma.
PG  - 1235724
LID - 10.3389/fimmu.2023.1235724 [doi]
LID - 1235724
AB  - BACKGROUND: New treatment strategies are needed to improve outcomes for patients 
      with advanced cholangiocarcinoma (CCA) due to the limited efficacy of current 
      first-line chemotherapy regimens. Although the combination of hepatic arterial 
      infusion chemotherapy (HAIC), lenvatinib, and programmed cell death protein-1 
      (PD-1) inhibitors has been extensively evaluated in the treatment of advanced 
      hepatocellular carcinoma, their roles in advanced CCA remain poorly understood. 
      The purpose of this study is to compare the efficacy and safety of HAIC plus 
      lenvatinib with or without PD-1 inhibitors in patients with advanced CCA. 
      METHODS: Between March 2019 to June 2022, patients diagnosed with advanced CAA 
      who received HAIC plus lenvatinib with or without PD-1 inhibitors treatment were 
      reviewed for eligibility. Efficacy was evaluated according to survival and tumor 
      response, and safety was evaluated according to the incidence of adverse events 
      (AEs). RESULTS: Fifty-five patients with advanced CCA were included in the study, 
      and they were divided into the HAIC+lenvatinib (LEN)+PD-1 inhibitors (PD-1i) 
      group (n = 35) and HAIC+LEN group (n = 20). The median follow-up time was 14.0 
      (5-42) months. Patients in the HAIC+LEN+PD-1i group had significantly better PFS 
      (HR = 0.390; 95% CI 0.189-0.806; p = 0.001) and OS (HR = 0.461; 95% CI 
      0.229-0.927; p = 0.01) than those in the HAIC+LEN group. The HAIC+LEN+PD-1i group 
      showed a higher objective response rate and disease control rate than the 
      HAIC+LEN group but did not find a significant difference. The incidence of grade 
      1-2 and grade 3-4 AEs was not significantly higher in the HAIC+LEN+PD-1i group 
      compared to the HAIC+LEN group, whereas two patients (5.7%) in the HAIC+LEN+PD-1i 
      group experienced grade 5 immune-mediated pneumonia. CONCLUSION: HAIC plus 
      lenvatinib with PD-1 inhibitors is safe and well-tolerated, and has the potential 
      to prolong the survival of patients with advanced CCA. The addition of PD-1 
      inhibitors may enhance the efficacy of HAIC and lenvatinib. Therefore, the 
      combined therapy has the potential to become a treatment option for advanced CCA.
CI  - Copyright (c) 2023 Wei, Wang, Wu, Liu, Wang, Ren, Yang, Chen and Zhang.
FAU - Wei, Zhanqi
AU  - Wei Z
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
AD  - School of Medicine, Tsinghua University, Beijing, China.
FAU - Wang, Yajing
AU  - Wang Y
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
AD  - School of Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Wu, Boyang
AU  - Wu B
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
AD  - School of Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Liu, Ying
AU  - Liu Y
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Wang, Yaqin
AU  - Wang Y
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Ren, Zhizhong
AU  - Ren Z
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Yang, Xiaowei
AU  - Yang X
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
FAU - Chen, Qian
AU  - Chen Q
AD  - Thorgene Co., Ltd., Beijing, China.
FAU - Zhang, Yuewei
AU  - Zhang Y
AD  - Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of 
      Clinical Medicine, Tsinghua University, Beijing, China.
AD  - School of Clinical Medicine, Tsinghua University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230830
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Humans
MH  - Apoptosis Regulatory Proteins
MH  - *Bile Duct Neoplasms/drug therapy
MH  - Bile Ducts, Intrahepatic
MH  - *Cholangiocarcinoma/drug therapy
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - *Liver Neoplasms/drug therapy
PMC - PMC10502306
OTO - NOTNLM
OT  - advanced cholangiocarcinoma
OT  - efficacy
OT  - hepatic arterial infusion chemotherapy
OT  - lenvatinib
OT  - programmed cell death protein-1 inhibitor
OT  - safety
COIS- Author QC was employed by the company Thorgene Co., Ltd. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/09/18 06:42
MHDA- 2023/09/19 06:43
PMCR- 2023/01/01
CRDT- 2023/09/18 04:36
PHST- 2023/06/06 00:00 [received]
PHST- 2023/08/15 00:00 [accepted]
PHST- 2023/09/19 06:43 [medline]
PHST- 2023/09/18 06:42 [pubmed]
PHST- 2023/09/18 04:36 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1235724 [doi]
PST - epublish
SO  - Front Immunol. 2023 Aug 30;14:1235724. doi: 10.3389/fimmu.2023.1235724. 
      eCollection 2023.